Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
NCT00160316
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
454
Enrollment
INDUSTRY
Sponsor class
Conditions
Postmenopause
Interventions
DRUG:
0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
Sponsor
Solvay Pharmaceuticals